In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation

European Journal of Pharmacology

Volumn 553, Issue 1-3, 2006, Pages 229-239

  Lu, Hua Rong ^a   Vlaminckx, Eddy ^a   Van de Water, Andre ^a   Rohrbacher, Jutta ^a   Hermans, An ^a   Gallacher, David J ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Action potential duration; Antibiotics; Drug induced long QT; Early afterdepolarizations; Long QT syndrome; TdP (Torsade de Pointes)

Indexed keywords

ERYTHROMYCIN; GREPAFLOXACIN; MOXIFLOXACIN; POTASSIUM CHANNEL HERG; SPARFLOXACIN; TELITHROMYCIN;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EMBRYO; FEMALE; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; ION CURRENT; ISOLATED HEART; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; PURKINJE FIBER; QT PROLONGATION; RISK ASSESSMENT; SCORING SYSTEM; TORSADE DES POINTES;

ACTION POTENTIALS; ANIMALS; ANTI-BACTERIAL AGENTS; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HEART VENTRICLES; HUMANS; LONG QT SYNDROME; PATCH-CLAMP TECHNIQUES; PERFUSION; PURKINJE FIBERS; RABBITS; RISK ASSESSMENT; TORSADES DE POINTES;

EID: 33751195492     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.09.035     Document Type: Article

References (37)

1. Adamantidis M.M., Dumotier B.M., Caron J.F., and Bordet R. Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers. Fundam. Clin. Pharmacol. 12 (1998) 70-76
2. Bischoff U., Schmidt C., Netzer R., and Pongs O. Effects of fluoroquinolones on HERG currents. Eur. J. Pharmacol. 406 (2000) 341-343
3. Cantalloube C., Bhargava V., Sultan E., Vacheron F., Batista I., and Montay G. Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment. Int. J. Antimicrob. Agents 22 (2003) 112-121
4. Chen X., Gass J.D., Bradley J.A., Dahm C.M., Sun Z., Kadyszewski E., Engwall M.J., and Zhou J. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br. J. Pharmacol. 146 (2005) 792-799
5. Carlsson L., Amos G.J., Andersson B., et al. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential?. J. Pharmacol. Exp. Ther. 282 (1997) 220-227
6. Champeroux P., Viaud K., EL-Amrani A.I., Fowler J.S., Martel E., Le Guennec J.Y., and Richard S. Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres. Br. J. Pharmacol. 144 (2005) 376-385
7. Daleau P., Lessard E., Groleau M.F., and Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea-pig ventricular myocytes. Angiology 48 (1995) 3010-3016
8. De Bruin M.L., Pettersson M., Meyboom R.H.B., Hoes A.W., and Leufkens H.G.M. Anti-HERG activity and the risk of drug-induced arrhythmia and sudden death. Eur. Heart. J. 26 (2005) 590-597
9. Demolis J.L., Charransol A., Funck-Brentano C., and Jailon P. Effects of a single dose of sparfloxacin on ventricular repolarization in healthy volunteers. Br. J. Clin. Pharmacol. 41 (1996) 499-503
10. Demolis J.L., Kubitza D., Tennezé L., and Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin. Pharmacol. Ther. 68 (2001) 658-666
11. Gintant G.A., Limberis J.T., McDermott J.S., Wegner C.D., and Cox B.F. The canine Purkinje fiber: an in-vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J. Cardiovasc. Pharmacol. 37 (2001) 607-618
12. Haverkamp W., Breithardt G., Camm A.G., Janse M.J., Rosen M.R., Antzelevitch C., Escande D., Franz M., Malik M., Moss A., et al. The potential for Qt prolongation and proarrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications: report on a policy conference on the European Society of Cardiology. Cardiovasc. Res. 47 (2000) 219-233
13. Hondeghem L.M., and Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential prolongation and proarrhythmiic drugs: importance of triangulation, reverse-use, and instability. J. Cardiovasc. Pharmacol. 41 (2003) 14-24
14. Hondeghem L.M., Lu H.R., van Rossenm K., and De Clerck F. Detection of proarrhythmia in the female rabbit heart: blinded validation. J. Cardiovasc. Electrophysiol. 14 (2003) 287-294
15. Hondeghem L.M., Carlsson L., and Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103 (2001) 2004-2013
16. Hondeghem L.M., Dujardin K., and De Clerck F. Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. Cardiovasc. Res. 50 (2001) 345-353
17. Iannini P.B. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin. Drug Saf. 1 (2002) 121-128 (Review)
18. Josefsson K., Bergan T., and Magni L. Dose-related pharmacokinetics after oral administration of a new formulation of erythromycin base. Br. J. Clin. Pharmacol. 13 (1982) 685-691
19. Joshi A., DiMino T., Vohra Y., Cui C., and Yan G.X. Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models. J. Electrocardiol. 37 (2004) 7-14 (Suppl)
20. Kavi J., Webberley J.M., Andrews J.M., and Wise R.A. Comparison of the pharmacokinetics and tissue penetration of spiramycin and erythromycin. J. Antimicrob. Chemother. 22 (1988) 105-110 (Suppl B)
21. Lu H.R., Mariën R., Saels A., and De Clerck F. Are there sex specific differences in ventricular repolarization or in drug-induced early afterdepolarizations in isolated rabbit Purkinje fibers?. Cardiovasc. Pharmacol. 36 (2000) 132-139
22. Lu H.R., Mariën R., Saels A., and De Clerck F. Species plays an important role in drug-induced prolongation of action potential duration and early afterdepolarizations in isolated Purkinje fibers. J. Cardiovasc. Electrophysiol. 12 (2001) 93-102
23. Lu H.R., Vlaminckx E., Teisman A., and Gallacher D.J. Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in-vitro in rabbit. J.P.T.M. 52 (2005) 90-105
24. Lubasch A., Keller I., Borner K., Koeppe P., and Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after signle oral administration in healthy volunteers. Antimicrob. Agents Chemother. 44 (2000) 2600-2603
25. Milberg P., Echardt L., Bruns H.J., Biertz J., Ramtin S., Reinsch N., Fleischer D., Kirchhof P., Fabritz L., Breithardt G., and Haverkamp W. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de points. J. Pharmacol. Exp. Ther. 303 (2002) 218-225
26. Montay G., Bruno R., Vergniol J.C., Ebmeier M., Le Roux Y., Guimart C., Frydman A., Chassard D., and Thebault J.J. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg. J. Clin. Pharmacol. 34 11 (1994) 1071-1076
27. Morganroth J., Talbot G.H., Dorr M.B., Johnson R.D., Geary W., and Magner D. Effect of single ascending. Supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval). Clin. Ther. 21 (1999) 818-828
28. Owens Jr. R.C. QT prolongation with antimicrobial agents: understanding the significance. Drugs 64 (2004) 1091-1124
29. Patmore L., Fraser S., Mair D., and Templeton A. Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration. Eur. J. Pharmacol. 406 (2000) 449-452
30. Rubinstein E., and Camm J. Cardiotoxicity of fluoroquinolones. J. Antimicrob. Chemother. 49 (2002) 593-596
31. Shah P.P. Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Saf. 28 (2005) 1009-1028
32. Shi J., Montay G., and Bhargava V.O. Clinical pahmacokinetics of telithromycin, the first ketolide antibacterial. Clin. Pharmacokinet. 44 (2005) 915-934
33. Stass H., Schuhly U., Moller J.G., and Delessen H. Effects of sucralfate on the oral bioavailability of moxifloxacin, a anovel 8-methoxyfluoroquinolone, in healthy volunteers. Clin. Pharmacokinet. 40 (2001) 49-55 (Suppl)
34. Volberg W.A., Koci B.J., Su W., Lin J., and Zhou J. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J. Pharmacol. Exp. Ther. 302 (2002) 320-327
35. Wu Y., Carlsson L., Liu T., Kowey P.R., and Yan G.-X. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of Torsades de Pointes. J. Cardiovasc. Electrophysiol. 16 (2005) 898-904
36. Yan G.-X., and Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 98 (1998) 1928-1936
37. Yan G.-X., Wu Y., Liu T., Wang J., Marinchak R.A., and Kowey P.R. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 103 (2001) 2851-2856